Moreover, in colorectal cancer patients’ tumor biopsies (C201), murlentamab treatment was associated with increased proportions of CD8+ and ICOS co-stimulatory molecule-positive cells in three out of four biopsies tested (Figure 1E). Here, CD8A is linked to neoplasm.